JDD Corner

JDD Issue Highlights | March 2022

The March 2022 issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, case reports, and editorials. With topics ranging from acne and psoriasis to Platelet Rich Plasma (PRP) for scarring alopecia and racial differences and their impact on treatment for hidradenitis suppurativa, we share this month’s issue highlights straight from the JDD Editor’s desk:

Adjunctive Use of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Treated With Ixekizumab examines the effectiveness and safety of adjunctive treatment in adult patients with chronic plaque psoriasis who have localized residual plaques.

Pooled Analysis Demonstrating Superior Patient-Reported Psoriasis Treatment Outcomes for Calcipotriene/Betamethasone Dipropionate Cream Versus Topical Suspension presents results from two phase 3, multicenter, randomized, investigator-blind, active, and vehicle-controlled trials evaluating 1271 patients with mild to moderate plaque psoriasis

In Vitro Rheology Predicts Improved Spreadability of Tazarotene 0.045% Lotion Versus Trifarotene 0.005% Cream quantitatively evaluates spreadability of two topical formulations for the treatment of acne.

A retrospective cross-sectional study of Dermoscopy and Reflectance Confocal Microscopy in Actinic Keratosis, Intraepithelial Carcinoma, and Invasive Squamous Cell Carcinoma defines morphological patterns and clinical applicability.

The Impact of Racial Differences on Treatment Strategies in Hidradenitis Suppurativa: A Retrospective Review explores management differences in HS patients.

Getting to the Core of Contemporary Therapies for Post-Inflammatory Hyperpigmentation discusses the epidemiology, pathogenesis, clinical presentation, and available treatment options for the PIH.

In Implications of Serum Anti Ceramide Antibodies and Interleukin 4 on Nerve Damage and Physical Impairments Among Leprotic Patients: A Case Controlled Study, anti-ceramide antibody (ACA) and IL-4 titers were estimated and correlated with the type of leprosy, disease duration, nerve damage, and disabilities.

Analysis of Reddit Reveals Dupilumab Questions Among Atopic Dermatitis Patients uncovers atopic dermatitis patients’ dupilumab-related information needs.

A Prospective, Multicenter Trial on the Efficacy and Safety of Poly-L-Lactic Acid for the Treatment of Contour Deformities of the Buttock Regions collected various safety and clinical efficacy parameters including subject satisfaction, skin hydration, elasticity, scaliness, roughness, and 3-dimensional imagery.

Extrafacial Merkel Cell Carcinoma Presenting as a Cyst reports two cases of extrafacial MCC.

Platelet Rich Plasma for the Treatment of Scarring Alopecia Due to Discoid Lupus Erythematosus suggests clinical benefit with the use of PRP as a treatment for cicatricial alopecia

Refractory Dissecting Cellulitis of the Scalp Treated With Risankizumab presents a case of risankizumab, an IL-23 inhibitor, used to successfully treat DC.

In mTOR Inhibitor-Induced Transient Acantholytic Dermatitis, identifying likely AE’s and how to treat them will allow clinicians to focus on the benefits of mTOR inhibitor therapies.

Successful Treatment of Cheilitis Granulomatosa With Certolizumab and Ustekinumab is reported in a patient with a history of ulcerative colitis and psoriasis.

Find more JDD Issue Highlights here